A kinase inhibitor screen reveals protein kinase C-dependent endocytic recycling of ErbB2 in breast cancer cells

J Biol Chem. 2014 Oct 31;289(44):30443-30458. doi: 10.1074/jbc.M114.608992. Epub 2014 Sep 15.

Abstract

ErbB2 overexpression drives oncogenesis in 20-30% cases of breast cancer. Oncogenic potential of ErbB2 is linked to inefficient endocytic traffic into lysosomes and preferential recycling. However, regulation of ErbB2 recycling is incompletely understood. We used a high-content immunofluorescence imaging-based kinase inhibitor screen on SKBR-3 breast cancer cells to identify kinases whose inhibition alters the clearance of cell surface ErbB2 induced by Hsp90 inhibitor 17-AAG. Less ErbB2 clearance was observed with broad-spectrum PKC inhibitor Ro 31-8220. A similar effect was observed with Go 6976, a selective inhibitor of classical Ca(2+)-dependent PKCs (α, β1, βII, and γ). PKC activation by PMA promoted surface ErbB2 clearance but without degradation, and ErbB2 was observed to move into a juxtanuclear compartment where it colocalized with PKC-α and PKC-δ together with the endocytic recycling regulator Arf6. PKC-α knockdown impaired the juxtanuclear localization of ErbB2. ErbB2 transit to the recycling compartment was also impaired upon PKC-δ knockdown. PMA-induced Erk phosphorylation was reduced by ErbB2 inhibitor lapatinib, as well as by knockdown of PKC-δ but not that of PKC-α. Our results suggest that activation of PKC-α and -δ mediates a novel positive feedback loop by promoting ErbB2 entry into the endocytic recycling compartment, consistent with reported positive roles for these PKCs in ErbB2-mediated tumorigenesis. As the endocytic recycling compartment/pericentrion has emerged as a PKC-dependent signaling hub for G-protein-coupled receptors, our findings raise the possibility that oncogenesis by ErbB2 involves previously unexplored PKC-dependent endosomal signaling.

Keywords: Breast Cancer; Confocal Microscopy; Endocytic Traffic; Endocytosis; ErbB2; High-Content Fluorescence Microscopy; Kinase Inhibitors; Protein Kinase C (PKC); Receptor Tyrosine Kinase; Small Molecule Screening.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, Non-P.H.S.

MeSH terms

  • Antineoplastic Agents / pharmacology*
  • Benzoquinones / pharmacology
  • Breast Neoplasms
  • Carbazoles / pharmacology
  • Carcinogenesis / metabolism
  • Cell Line, Tumor
  • Drug Screening Assays, Antitumor
  • Endocytosis / drug effects
  • Endosomes / metabolism
  • Enzyme Activation
  • Extracellular Signal-Regulated MAP Kinases / metabolism
  • Feedback, Physiological
  • Female
  • Humans
  • Indoles / pharmacology
  • Lactams, Macrocyclic / pharmacology
  • MAP Kinase Signaling System
  • Phosphorylation
  • Protein Kinase C-alpha / antagonists & inhibitors
  • Protein Kinase C-alpha / metabolism*
  • Protein Kinase C-delta / antagonists & inhibitors
  • Protein Kinase C-delta / metabolism*
  • Protein Kinase Inhibitors / pharmacology*
  • Protein Processing, Post-Translational
  • Protein Transport
  • Receptor, ErbB-2 / metabolism*

Substances

  • Antineoplastic Agents
  • Benzoquinones
  • Carbazoles
  • Indoles
  • Lactams, Macrocyclic
  • Protein Kinase Inhibitors
  • Go 6976
  • tanespimycin
  • ERBB2 protein, human
  • Receptor, ErbB-2
  • PRKCA protein, human
  • PRKCD protein, human
  • Protein Kinase C-alpha
  • Protein Kinase C-delta
  • Extracellular Signal-Regulated MAP Kinases
  • Ro 31-8220